Rat CD30 Ligand / TNFSF8 Protein (Cytokine)

Tumor necrosis factor (ligand) superfamily, member 8 Protein Datasheet

CD30 Ligand / TNFSF8 Protein Product Information

• Synonym: TNFSF8
• Protein Construction: A DNA sequence encoding the ratTNFSF8(Gln66-Asp237) was expressed with Fc region of human IgG1 at the N-terminus.
• Source: Rat
• Expression Host: Human Cells

CD30 Ligand / TNFSF8 Protein QC Testing

• Purity: > 90 % as determined by SDS-PAGE
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Glu
• Molecular Mass: The recombinant rat TNFSF8 comprises 432 amino acids and predicts a molecular mass of 47.9 kDa. The apparent molecular mass of the recombinant protein is approximately 58 kDa in SDS-PAGE under reducing conditions due to glycosylation.
• Formulation: Lyophilized from sterile PBS, pH 7.4.
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: CD30 Ligand / TNFSF8 protein

CD30 Ligand / TNFSF8 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

CD30 Ligand / TNFSF8 Protein Description

CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a cytokine belonging to the emerging tumor necrosis factor (TNF) ligand superfamily, and is a specific ligand for CD30/ TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response.

References

1. Gruss HJ. et al.,1994, Blood. 83: 2045-56.
2. Croager EJ. et al., 1997, Biochim Biophys Acta 1353: 231-5.
3. Wendtner CM. et al., 1995, Cancer Res. 55: 4157-61.
4. Fischer M. et al., 2006, J Clin Invest. 116: 2748-56.
5. Blazar BR. et al., 2004, J Immunol. 173: 2933-41.